Cognitive remediation therapy for patients with bipolar disorder: A randomised proof‐of‐concept trial

• DOI: 10.1111/bdi.12968
• Publication Date: 2020-06-25T06:47:32Z
• Authors: Rebecca Strawbridge; Dimosthenis Tsapekos; John Hodsoll; Tim Mantingh; Nefize Yalin; Paul McCrone; Janet Boadu; Karine Macritchie; Matteo Cella; Clare Reeder; Jessica Fish; Til Wykes; Allan H. Young
• Keywords: Cognitive remediation therapy

Cognitive remediation therapy (CRT) may benefit people with bipolar disorder type I and II for whom cognitive impairment is a major contributor to disability. Extensive research has demonstrated CRT improve cognition psychosocial functioning in different diagnoses, but randomised trials of evidenced programmes are lacking disorders. The Remediation Bipolar (CRiB) study aimed determine whether an established programme feasible acceptable disorders.This proof-of-concept, single-blind trial recruited participants aged 18-65 disorder, not currently experiencing episode. They were 1:1 block treatment-as-usual (TAU) or without individual 12 weeks. partly computerised ("CIRCuiTS") was therapist-led evidence-based from those psychotic illnesses. Data collected analysed by investigators blinded group allocation. main outcomes (week 13 25) examined participant retention, intervention feasibility putative effects on via intention-to-treat analyses.ISRCTN ID32290525.Sixty (02/2016-06/2018) (n = 29) TAU 31). Trial withdrawals equivalent (CRT n 2/29; 5/31). satisfaction indicated high acceptability. Intention-to-treat analyses (N 60) greater improvements CRT- than TAU-randomised participants: at both week 25, CIRCuiTS showed larger the following domains 25 effect sizes reported here): IQ (SES 0.71, 95% CI [0.29,1.13]), working memory 0.70, [0.31,1.10]), executive function 0.93, [0.33,1.54]), 0.49, [0.18,0.80]) goal attainment 2.02, [0.89,3.14]). No serious adverse events reported.CRT individuals disorders enhance functioning. this proof-of-concept encourage further investigation definitive trial.